Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Feb;42(2):358-61.
doi: 10.1128/AAC.42.2.358.

Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir

Affiliations

Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir

G L Drusano et al. Antimicrob Agents Chemother. 1998 Feb.

Abstract

While CD4 cell counts are widely used to predict disease progression in human immunodeficiency virus (HIV)-infected patients, they are poorly explanatory of the progression to AIDS or death after the introduction of chemotherapy. Changes in HIV load (as measured by RNA PCR) have been shown to be a much better predictor of the risk of disease progression. Since the interrelationship of these markers is of great clinical interest, we modeled the time-averaged return of CD4 cell count and change in viral load subsequent to therapy with the HIV protease inhibitor indinavir. We found that CD4 cell return was significantly related to both the baseline CD4 count (r2 = 0.86, P < 0.001) and the decline in HIV RNA PCR-determined viral load (also referred to in this work as the HIV RNA PCR decline) (r2 = 0.60, P < 0.01). Simultaneously modeling both influences in a linked nonlinear model (r2 = 0.93, P < 0.001) demonstrated that (i) the starting number of CD4 cells accounted for the majority of the change in CD4 cell return and (ii) the return of CD4 cells attributable to viral load decrease was 50% of maximal with only a decrease of approximately 0.2 log of HIV RNA as modeled from the first 12 weeks of therapy. Much greater viral inhibition beyond that necessary for maximal CD4 cell return is possible. Given that HIV RNA PCR decline is more strongly linked to ultimate clinical course in HIV disease, our findings indicate that CD4 return is potentially misleading as an indicator of antiviral effect, since it is determined more by the starting CD4 value than by viral load decline and since near-maximal changes occur with minimal antiviral effect.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
CD4 return with indinavir therapy and effect of RNA drop and starting CD4 count. The three-dimensional plot of CD4 cell return as a function of both baseline CD4 cell count and the modeled HIV RNA PCR decline induced by indinavir therapy is shown. The lines defining the edges of the surface are the direct two-dimensional relationships, with the response surface showing the interactive effect. It is clear that the amount of CD4 cell return attributable to viral load decline is maximal at very low values of HIV RNA PCR change. The equation for the surface is Average number of CD4 cells with therapy (cells/milliliter) = 110.3*{(log RNA decline)26.1/[(log RNA decline)26.1 + 0.09826.1]} + 534.6*{(starting number of CD4 cells)0.98/[(starting number of CD4 cells)0.98 + 291.30.98]}. The model fits the data quite well (r2 = 0.93, P < 0.001).

References

    1. Cavert W, Staskus K, Zupanic M, Wietgrefe S, Notermans D, Danner S, Henry K, Mills R, Haase A T. Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C. 1997. Quantitative in situ hybridization measurement of HIV-1 RNA clearance kinetics from lymphoid tissue cellular compartments during triple drug therapy, abstr. LB9.
    1. Cohen O J, Pantaleo G, Holodniy M, Fox C H, Orenstein J M, Schnittman S, Niu M, Graziosi C, Pavlakis G N, Lalezari J, Bartlett J A, Steigbigel R T, Cohn J, Novak R, McMahon D, Bilello J, Fauci A S. Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes. J Infect Dis. 1996;173:849–856. - PubMed
    1. Collier A C, Bozzette S, Coombs R W, Causey D M, Schoenfeld D A, Spector S A, Petinelli C B, Daivies G, Richman D D, Leedom J M, Kidd P, Corey L. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med. 1990;323:1015–1021. - PubMed
    1. D’Argenio D Z, Schumitzky A. ADAPT II user’s guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles, Calif: Biomedical Simulations Resource; 1997.
    1. De Jong M D, Veenstra J, Stilianakis N I, Schuurman R, Lange J M A, DeBoer R J, Boucher C A B. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc Natl Acad Sci USA. 1996;93:5501–5506. - PMC - PubMed

Publication types